ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure. |
On November 22, 2016, Zosano Pharma Corporation issued a press
release announcing the sale of a nonstrategic asset. A copy of
the press release is hereby furnished to the Commission as
Exhibit 99.1 and incorporated by reference herein.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
ExhibitNo. |
Description |
|
| 99.1 |
Press release of Zosano Pharma Corporation, dated November 22, 2016 |
2
About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon. ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Recent Trading Information
ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) closed its last trading session down -0.050 at 0.640 with 549,551 shares trading hands.